会上，还举行了签约仪式，奈杜集团、睿微讯科、矽池半导体、摩尔星核、一心堂（002727）柏安、辽 翔动力等6家企业签约入驻算力小镇。同时，小镇企业星物种机器人与强脑科技、徴格半导体与申昊科 技也达成了战略合作,这标志着算力小镇在人工智能产业链构建、整合与生态完善上又迈出了关键一 步，进一步实现了"引新聚优"与"本土协同"的双向突破。 值得一提的是，本次活动举办地算力小镇是全国首个以"算力"命名、长三角唯一以"算力"为产业导向的 特色小镇，2025年成功获批杭州市第一批人工智能产业创新空间、入选第八批浙江省特色小镇创建名 单。自2021年开园以来，小镇聚焦集成电路设计和人工智能两大核心产业，集聚知存科技、智诊科技、 ZYNALOG徴格半导体等企业超2600家。短短四年间，算力小镇不仅完成了从0到1的产业积淀，更实现 了从"算力单点突破"到"产业生态共荣"的能级跃升。 12月12日，2025长三角人工智能产业融合共生发展大会在杭州临平算力小镇举行。活动的主办方浙江图 灵算力研究院是浙江省委网信办指导下成立的高能级平台，布局人工智能、集成电路等高端业态，通过 提供产业研究、战略咨询、市场对接、资本助力等服务，助推生 ...

一心堂药业集团股份有限公司 2025 年度第四次临时股东会暨中小投资者表决结果公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-139 号 1.本次股东会没有增加、否决或变更提案。 2.本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议时间：2025 年 12 月 10 日（星期三）下午 14 点。 （2）网络投票时间：2025 年 12 月 10 日。其中，通过深圳证券交易所交易系统进行网络 投票的具体时间为 2025 年 12 月 10 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳 证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 12 月 10 日上午 9:15 至下午 15:00 的任意时间。 2.召开地点：云南省昆明市经济技术开发区鸿翔路 1 号会议室 3.召开方式：现场投票及网络投票 4.召集人：本公司董事会 5.主持人：董事长阮鸿献先生。 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于一心堂药业集团股份有限公司 本所在此同意，公司可以将本法律意见书作为本次股东会公告的法定文件， 随其他公告文件一并提交深圳证券交易所予以审核公告。 本所律师根据《股东会规则》第六条的要求，按照律师行业公认的业务标准、 1 道德规范和勤勉尽责精神，对本次股东会的召集和召开的有关事实及公司提供的 文件进行了核查和验证，并对本次股东会进行现场见证，现出具法律意见如下： 一、本次股东会的召集、召开程序 1、本次股东会的召集程序 本次股东会由公司董事会根据于2025年11月20日召开的公司第七届董事会 第一次临时会议决议召集。经本所律师查验，公司董事会于2025年11月21日在《证 券时报》《中国证券报》《证券日报》及巨潮资讯网上刊登了《一心堂药业集团 股份有限公司关于召开2025年度第四次临时股东会的通知》（以下简称"会议通 知"）。 2025 年度第四次临时股东会的法律意见书 致：一心堂药业集团股份有限公司 根 ...

Core Insights - The pharmaceutical distribution industry is a crucial component of the national healthcare system and health industry, significantly impacting public health and safety [1][7] - The industry is experiencing growth due to the implementation of the "two-invoice system" reform and increasing public awareness of healthcare [1][7] Industry Overview - The pharmaceutical distribution market in China is projected to reach a sales volume of 29,470 billion yuan in 2024, with wholesale sales accounting for 22,970 billion yuan (77.94%) and retail sales for 6,500 billion yuan (22.06%) [1][7] - The regional distribution of sales shows that East China accounts for 36.3%, Central South 27.0%, North China 15.2%, Southwest 13.4%, Northeast 4.3%, and Northwest 3.8%, with the top three regions contributing to 78.5% of total sales [9][10] Sales Structure - The sales composition indicates that Western medicine accounts for 70.8% of total sales, followed by traditional Chinese medicine at 14.6%, medical devices at 7.7%, and other categories [9][10] Current State of the Industry - As of the end of 2024, there are 705,400 licensed pharmaceutical businesses in China, including 15,100 wholesale companies and 66,070 retail chain enterprises [3][5] - The total number of retail pharmacies has increased to 683,700, with a notable rise in single retail pharmacies [3][5] Financial Performance - In 2024, the main business income of reported pharmaceutical distribution enterprises reached 22,431 billion yuan, reflecting a 0.8% increase from 2023, while the profit totaled 468 billion yuan with an average gross margin of 7.2% [5][6] Industry Chain - The pharmaceutical distribution industry serves as a critical link in the pharmaceutical supply chain, connecting manufacturers with end-users, including hospitals and pharmacies [11][12] Competitive Landscape - Major players in the pharmaceutical distribution sector include East China Pharmaceutical, Shanghai Pharmaceutical, China National Pharmaceutical Group, and others, with significant revenue contributions from these companies [14][15] Future Development Directions - The industry aims to enhance operational efficiency and inventory management to ensure a stable supply of pharmaceuticals while minimizing financial risks [18][19]

Core Insights - The National Health Commission reported that 17 provinces in China are experiencing high levels of influenza activity, with a positive rate of 51% for flu virus tests among patients with flu-like symptoms [1] - In response to the urgent need for respiratory health protection during the flu season, Kunming Pharmaceutical Group and Yixintang Pharmaceutical initiated the "Clear Lung Action" campaign to promote public awareness of respiratory health and scientific prevention methods [1] Group 1 - The "Clear Lung Action" event featured interactive activities where citizens learned about health, received themed gifts, and engaged in various functional areas, including a large lung-clearing device that attracted many participants [2] - Medical experts provided insights on the relationship between influenza and lung health, symptom recognition, and scientific prevention methods, while free consultations were offered to the public [2] - Participants could measure their lung capacity and function through the "One Breath Lung Challenge," and learn practical lung health maintenance methods through exercises that combine traditional and modern techniques [2] Group 2 - The core concept of the "Clear Lung Action" is based on Kunming Pharmaceutical Group's flagship product, "Kun Traditional Chinese Medicine Clear Lung Phlegm Pill," which has historical roots dating back to the Song Dynasty and is known for its efficacy in clearing lungs and relieving cough [3] - Kunming Pharmaceutical Group's subsidiary, Kun Traditional Chinese Medicine, is recognized as the "oldest pharmaceutical company" by Guinness World Records and has been awarded the "Chinese Time-Honored Brand" honor [3] - Yixintang, a leading retail pharmacy chain in China, operates over 11,230 stores and serves approximately 210 million customers annually, enhancing the reach of health education initiatives [3] Group 3 - The collaboration between leading pharmaceutical companies and large retail pharmacy chains is advancing health education from one-way communication to interactive engagement, emphasizing preventive health measures in the context of the "Healthy China" strategy [4] - The "Clear Lung Action" effectively integrates traditional Chinese medicine's preventive wisdom with contemporary health management practices to safeguard public respiratory health [4]

Investment Rating - The report maintains an "Overweight" rating for the retail chain pharmacy industry [1][3]. Core Insights - The report highlights that leading pharmacies are beginning to recover from a challenging phase, with a focus on the growth potential in 2026 driven by both organic and external factors [2][3]. - The retail pharmacy market in China is projected to reach a retail scale of 611.9 billion yuan in 2024, reflecting a year-on-year decline of 1.8% due to factors such as population decrease and changes in healthcare insurance [3]. - The report identifies key companies to watch, including Yifeng Pharmacy, Dazhenglin, and Laobaixing, while also suggesting attention to Yixintang, Jianzhijia, and Shuyupingmin [3]. Summary by Sections Market Overview - The retail pharmacy market is experiencing a contraction in supply due to increased competition, with the number of physical pharmacies exceeding 700,000 in 2024, a 60% increase since 2014 [3]. - The report notes a recovery trend in the market, with a sequential growth of 6.7% in September 2025, despite a year-on-year decline of 1.9% in the first three quarters of 2025 [3]. Demand and Supply Dynamics - The demand side is showing signs of recovery, particularly in essential medicine categories, with a 6.9% sequential growth in drug retail sales in September 2025 [3]. - The report indicates that the concentration of leading pharmacy chains is expected to increase as smaller chains face operational challenges, leading to closures [3]. Future Outlook - The report anticipates that leading pharmacy chains will achieve recovery through both internal growth driven by rising flu cases and external growth via acquisitions, with a current low penetration of direct stores at about 1.5% [3][4]. - The long-term outlook remains positive for industry concentration, with expectations for continued growth in the leading pharmacy chains [3].

Group 1 - The company Yixin Tang (002727) confirmed on an interactive platform that its stores are selling products related to Xingqi Eye Medicine (300573) [1]

（记者 胡玲） 每经AI快讯，一心堂（002727.SZ）12月3日在投资者互动平台表示，一心到家有美容个护及日用百货等 品类。 ...

Group 1 - The company plans to complete a stock repurchase of 135 million yuan using its own funds in 2024 and will complete an additional repurchase of 150 million yuan at the beginning of 2025 [1] - The shares repurchased in 2025 will be registered in the company's securities account as treasury stock [1] - Currently, there are no new stock repurchase plans beyond the mentioned amounts [1]

Summary of Conference Call on Pharmacy Sector Industry Overview - The pharmacy sector is showing signs of recovery, with positive signals from industry policies and adjustments made by pharmacies, particularly leading pharmacies like YaoXingTang, which have achieved same-store sales growth through adjustments [1][2] - The three main trends in the pharmacy industry are prescription outflow, increased industry concentration, and diversified operations [1][3] Key Points Recovery Indicators - The pharmacy sector has been consolidating at the bottom for about a year since 2024, with leading pharmacies currently at historical valuation lows [2] - Positive changes in industry policies and pharmacy operations are evident, indicating a clear upward trend [2] Major Trends 1. **Prescription Outflow**: This long-term trend significantly contributes to increased customer traffic and sales, although online prescription transfer remains slow [3] 2. **Industry Concentration**: The concentration of the top ten pharmacies in China is around 30%, compared to 80% in Japan and 70% in the US, indicating substantial room for growth [3] 3. **Diversified Operations**: Successful implementation of comprehensive adjustments by leading pharmacies in 2026 is expected to significantly boost profits [4] Company Performances - **Yifeng Pharmacy**: Designated as a "gold stock" for December, with a valuation offering good value. Same-store sales are expected to recover to over 1% growth starting Q3 2025, with projected revenue growth returning to double digits in 2026, corresponding to a PE ratio of less than 14 [5] - **Dafeng Pharmaceutical**: Achieved a profit growth of 26% in the first three quarters of 2025, with a net profit margin increasing from 3% to nearly 6%. The company plans to restart its acquisition strategy, which is expected to support future performance [6] - **Laobaixing Pharmacy**: Same-store sales turned positive starting Q3 2025, with significant contributions from acquisitions. The company is also making progress in store adjustments [7] Future Expectations - **Yifeng Pharmacy**: Expected to see improved performance in 2026, with revenue growth projected to exceed double digits and a PE ratio of less than 14, indicating a favorable investment position [5] - **Dafeng Pharmaceutical**: Anticipated to achieve over 30% net profit growth for the year, with a strong performance trend continuing into the future [6] - **Yifeng Pharmacy's Adjustments**: Plans to increase the non-pharmaceutical product ratio to 40% over the next three to five years, with significant profit contributions expected from store adjustments [7] Industry Adjustments and Projections - The pharmacy sector is expected to conduct pilot adjustments in 150 stores in 2025, with plans for comprehensive adjustments in 2026. Adjusted stores are projected to achieve a sales share of over 30%, with daily sales increasing by 1,200 yuan and gross margins improving by 18% [7] - If 70% of stores implement these adjustments, the net profit increase could exceed 500 million yuan [7] Investment Opportunities - The pharmacy sector has largely moved past policy disruptions, with ongoing improvements in same-store sales and increasing industry concentration. Leading pharmacies are now at attractive valuation levels, with growth certainty in performance [9] - Recommendations include focusing on opportunities within the pharmacy sector, particularly on stable-performing leading pharmacies like Yifeng and Dafeng [9] Data Evaluation - Data Evaluation is actively expanding and collaborating with Taiwan's Dashi Pharmacy for pilot projects in Shandong, showing optimism for future performance despite limited current data [10]